age, and it is considered to be a sensitive index of renal disease (2-5), an early warning of rejection after renal transplantation (6, 7), and a sign of drug nephrotoxicity in humans (8-10) and nninjsila (11,12). Clinical applications of NAGase assay to the detection of renal disturbance in patients with diabetes mellitus or hypertension and in screening children with renal disease also have attracted attention (13) (14) (15) .
age, and it is considered to be a sensitive index of renal disease (2) (3) (4) (5) , an early warning of rejection after renal transplantation (6, 7) , and a sign of drug nephrotoxicity in humans (8-10) and nninjsila (11,12). Clinical applications of NAGase assay to the detection of renal disturbance in patients with diabetes mellitus or hypertension and in screening children with renal disease also have attracted attention (13) (14) (15) .
NAGase activity has been determined fluorimetrically with 4-methylunibelliferyl N-acetyl--n-g1ucosaminide (4MLJ-NAG) (16) and coiprimetrically with p-mtrophenyl N- (17) Urine samples We used untimed urine specimens, from among the routine clinical specimens submitted to Shionogi Clinical Laboratories.
acetyl-fl-1)-glucosaminide (PNP-NAG)
Urine samples from normal healthy subjects were used to establish the assay conditions.
Enzyme assay. In the MCP-NAG method, the substrate solution (1.() mL, pH 4.90), which contained 2.75 mmol of MCP-NAG and 3.07 mniol of borax per liter of citrate buffer (50 mmol/L, pH 4.75), was preincubated for 5 mm at 37#{176}C.
A 50-4, urine sample was added and the mixture was incubated for a further 15 mm at 37#{176}C. The reaction was terminated by adding 2.0 mL of 0.3 moIIL sodium carbonate and the absorbance at 580 nm was measured. As the substrate blank, distilled water was substituted for the urine sample.
In the fluorimetric procedure, 0. uronidase were determined by using 5 rnmollL solutions of the p-mtrophenyl glycosides of each sugar as substrates, according to the MCP-NAG method.
One unit of enzyme activity is defined as the amount of enzyme catalyzing the formation of 1 mol of the aglycone per minute under the conditions described above.
Synthesis of MCP-NAG. Figure 1 glucosamine (Figure 2 ). MCP and MCP-NAG show absorption maxima at 580 and 414 nm, respectively. The released MCP can be measured in alkaline solution at 580 nm by subtracting the absorbance of MCP-NAG substrate blank. Properties of human urinary NAGase were investigated. The pH is optimum between 4.75 and 5.25 (Figure 3) . The reaction proceeds linearly for 30 mm at 37 #{176}C and for 20 mm at 45 #{176}C (Figure 4) . NAGase is inactivated gradually at 50#{176}C, rapidly at 60#{176}C. We calculated the Km value for MCP-NAG to be 0.41 mmol/L from the plot of S/V0 vs S (Figure 5) .
Blank values for the MCP-NAG and PNP-NAG methods were compared by using urine samples of light to deep colors ( Table 1 ). The PNP-NAG method gave relatively high urine blanks, which were roughly parallel to color density and in the range of 1.6 to 5.2 UIL equivalent NAGase activity. Table 2 gives information on the within-assay and between-assay variations on three levels for urine samples. The precision of the MCP-NAG method seems acceptable.
The mean analytical recovery of bovine-kidney NAGase, with NAGase. We used a substrate solution of 2.75 mmol/L, which is about seven times the Km. The initial velocity was estimated to be 87% of Vmax. The within-assay and between-assay variations were acceptable, and results correlated well with those by the 4MU-NAG method.
4MU-NAG method (U/L)
Clearly, our MCP-NAG method has several advantages over conventional methods for determining NAGase activity in the urine, and it may be useful for clinical studies or for other uses in which many samples are to be tested.
